Skip to main content

Table 1 Treatment-specific changes from baseline from LEAD-1 Study

From: Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

 

Liraglutide 1.8 mg

Liraglutide 1.2 mg

Rosiglitazone 4 mg

 

Mean change

SD

Mean change

SD

Mean change

SD

HbA1c (%)

-1.13*

1.05

-1.08*

1.04

-0.44

1.05

SBP (mmHg)

-2.81

13.07

-2.56

12.72

-0.93

12.71

Total cholesterol (mg/dl)

-11.99*

37.97

5.06

37.31

7.42

37.14

LDL (mg/dl)

-8.09*

29.85

-2.36

29.28

4.43

29.15

HDL (mg/dl)

-1.57*

7.50

-0.84

7.28

0.75

7.23

Triglycerides (mg/dl)

-14.72*

132.28

-17.64*

130.23

1.73

129.63

BMI

-0.08*

1.11

0.12

1.13

0.78

1.13

Major hypoglycemic event/year

0.01

 

0

 

0

 

Minor hypoglycemic event/year

0.47

 

0.50

 

0.12

 
  1. *Statistically significant (p < 0.05) compared to rosiglitazone 4 mg.
  2. BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.